Next, to further clarify whether the RAS/RAF pathway was involved in ALDH2-mediated PTX resistance, we overexpressed KRAS and RAF1, and determined the efficacy of PTX in ALDH2 knockdown NSCLC/PTX cells (Fig. S6C). The gene discussed is RAF1; the disease is non-small cell lung carcinoma.